Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 9:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,594 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Tumors, Central Nervous System Clear all
Recruiting Phase 1Phase 2 Interventional

Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

NCT01906385
View directory record Official record
Conditions
Glioma
Interventions
Rhenium Liposome Treatment
Drug
Lead sponsor
Cerenome
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
3
States / cities
Manhasset, New York • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 25, 2026, 9:02 PM EDT
Completed Phase 1 Interventional

BMS-247550 in Treating Patients With Advanced Cancers

NCT00006221
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ixabepilone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 25, 2026, 9:02 PM EDT
Terminated Phase 1Phase 2 Interventional

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

NCT05500508
View directory record Official record
Conditions
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
Interventions
AMXT1501, DFMO
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Sep 25, 2026, 9:02 PM EDT
Completed Phase 1Phase 2 Interventional

COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors

NCT00004147
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
incyclinide
Drug
Lead sponsor
New Approaches to Brain Tumor Therapy Consortium
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 25, 2026, 9:02 PM EDT
Completed Phase 1 Interventional

CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas

NCT00074243
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
CC-8490
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 25, 2026, 9:02 PM EDT
Withdrawn Phase 3 Interventional

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

NCT00226668
View directory record Official record
Conditions
Brain Edema, Brain Tumor
Interventions
hCRF, placebo hCRF
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • Newport Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2008 · Synced Sep 25, 2026, 9:02 PM EDT
Completed Phase 1 Interventional

Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis

NCT00185848
View directory record Official record
Conditions
Brain Cancer, Arthritis, Rheumatoid, Central Nervous System Neoplasms, Glioma
Interventions
[18F]FHBG
Radiation
Lead sponsor
Sanjiv Sam Gambhir
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Los Angeles, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 25, 2026, 9:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Social Work Intervention Focused on Transitions

NCT02232126
View directory record Official record
Conditions
Study Focus: 30-day Rehospitalizations Among At-risk Older Adults Randomized to a Social Work-driven Care Transitions Intervention, Heart Disease, Diabetes, Hypertension, Cancer, Depression, Asthma, Chronic Heart Failure, Chronic Obstructive Pulmonary Disease, Stroke
Interventions
SWIFT home intervention
Other
Lead sponsor
University of Southern California
Other
Eligibility
65 Years to 110 Years
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Los Angeles, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Sep 25, 2026, 9:02 PM EDT
Completed Phase 1Phase 2 Interventional

Immunotoxin Therapy in Treating Patients With Malignant Glioma

NCT00006268
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
cintredekin besudotox, isolated perfusion, conventional surgery
Biological · Drug · Procedure
Lead sponsor
New Approaches to Brain Tumor Therapy Consortium
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
11
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 25, 2026, 9:02 PM EDT
Terminated Phase 1 Interventional Results available

Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors

NCT03050450
View directory record Official record
Conditions
Central Nervous System Tumors
Interventions
25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
1 Year to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Sep 25, 2026, 9:02 PM EDT
Completed No phase listed Observational

Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptability of a Supportive Intervention

NCT06168825
View directory record Official record
Conditions
Cancer, Breast Cancer, Brain Cancer, Central Nervous System Cancer, Colorectal Cancer, Esophageal Cancer, Gynecologic Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Melanoma, Blood Cancer, Lung Cancer, Acceptance and Commitment Therapy, Mind-Body Therapies, Psychosocial Intervention
Interventions
Mind Over Matter (MOM)
Other
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 25, 2026, 9:02 PM EDT
Terminated Phase 3 Interventional

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

NCT03326674
View directory record Official record
Conditions
Breast Cancer
Interventions
Tesetaxel and Capecitabine, Capecitabine
Drug
Lead sponsor
Odonate Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
90
States / cities
Chandler, Arizona • Goodyear, Arizona • Tucson, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 25, 2026, 9:02 PM EDT
Completed Phase 1Phase 2 Interventional

Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma

NCT00003616
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 25, 2026, 9:02 PM EDT
Completed Not applicable Interventional Results available

A Study to Test Performance of Needle Placements for Neuraxial Procedures Using Tactile Imaging vs Control

NCT04796935
View directory record Official record
Conditions
Central Nervous System Infections, Pseudotumor Cerebri, Neurological Disorder, Cancer, Obstetric Procedure Pain, Orthopedic Procedure Pain, Post-Dural Puncture Headache
Interventions
Tactile Imaging (VerTouch), Control (palpation)
Device · Other
Lead sponsor
IntuiTap Medical, Inc
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Providence, Rhode Island • Charleston, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 25, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

NCT00381797
View directory record Official record
Conditions
Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma
Interventions
Bevacizumab, Fludeoxyglucose F-18, Irinotecan Hydrochloride
Biological · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
11
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2017 · Synced Sep 25, 2026, 9:02 PM EDT
Terminated Not applicable Interventional

Ketogenic Diet in Children With Malignant or Recurrent/Refractory Brain Tumor

NCT03328858
View directory record Official record
Conditions
Brain Tumors
Interventions
Ketogenic Diet
Other
Lead sponsor
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Other
Eligibility
12 Months to 35 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 25, 2026, 9:02 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab In Central Nervous System Metastases

NCT02886585
View directory record Official record
Conditions
Brain Metastases
Interventions
Pembrolizumab, MRI, PET/CT, Stereotactic Radiosurgery
Drug · Radiation · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 25, 2026, 9:02 PM EDT
Terminated Phase 2 Interventional Results available

Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

NCT00972335
View directory record Official record
Conditions
Intracranial Meningioma
Interventions
Everolimus, Bevacizumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Orlando, Florida • Louisville, Kentucky • Omaha, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 25, 2026, 9:02 PM EDT
Withdrawn No phase listed Observational

Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged

NCT05116618
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
InVisionFirst-Lung ctDNA assay
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 25, 2026, 9:02 PM EDT
Completed Phase 1 Interventional

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

NCT01222780
View directory record Official record
Conditions
Sarcoma, Neuroblastoma, Wilms Tumor, Leukemia, Lymphoma, Brain Tumors
Interventions
Marqibo
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
2 Years to 20 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 25, 2026, 9:02 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

NCT07336446
View directory record Official record
Conditions
Prostate Cancer
Interventions
AZD9750, AZD5305
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Duarte, California • San Francisco, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 25, 2026, 9:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis

NCT00285324
View directory record Official record
Conditions
Glioma Tumor Recurrence, Radiation Necrosis, Primary Brain Tumor
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
21 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 25, 2026, 9:02 PM EDT
Withdrawn Phase 1 Interventional

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

NCT01130623
View directory record Official record
Conditions
Sarcoma, Neuroblastoma, Wilms Tumor, Osteosarcoma, Brain Tumor
Interventions
Pazopanib (GW786034)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 25, 2026, 9:02 PM EDT
Completed Phase 1 Interventional

D2C7 for Adult Patients With Recurrent Malignant Glioma

NCT02303678
View directory record Official record
Conditions
Malignant Glioma, Brain Tumor, Recurrent
Interventions
D2C7-IT
Drug
Lead sponsor
Darell Bigner
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 25, 2026, 9:02 PM EDT